SCHEMBL24299757

SCHEMBL24299757

CC(C)c1nc2ccc(-c3nc4cc(N5CCN(C)CC5)ccc4[nH]3)cc2[nH]1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
TOP1 P11387 3/20 0.65
TOP2A P11388 3/20 0.65
HPGD P15428 1/20 0.65
HSD17B10 Q99714 1/20 0.65
MEN1 O00255 2/20 0.59
MAPT P10636 2/20 0.59
BLM P54132 2/20 0.59
KMT2A Q03164 2/20 0.59
SLCO2B1 O94956 1/20 0.59
GLA P06280 1/20 0.59
RECQL P46063 1/20 0.59
BCL2L1 Q07817 1/20 0.59
SLCO1B3 Q9NPD5 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
SLCO1B1 Q9Y6L6 1/20 0.59
TERT O14746 5/20 0.59
KDM4E B2RXH2 2/20 0.56
NPC1 O15118 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24299677 0.92 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL6587643 0.86 SMN1; SMN2 (0.69) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL19484928 0.86 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
Hoechst 33258 SCHEMBL18089342 0.85 ALDH1A1 (0.89) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14439319 0.84 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL8769012 0.81 ALDH1A1 (0.72) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL6587636 0.81 SMN1; SMN2 (0.69) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
Hoechst 33258 SCHEMBL13856958 0.81 ALDH1A1 (0.89) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14665474 0.81 SMN1; SMN2 (0.66) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL15969230 0.81 ALDH1A1 (0.90) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230366045-A1 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF PROMEGA CORPORATION 2023-11-16 US disclosed
US-20230366045-A1 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF PROMEGA CORPORATION 2023-11-16 US disclosed
US-20220064710-A1 NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF PROMEGA CORPORATION 2022-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230366045-A1 NUCLEIC ACID CROSSLINKING REAGENTS AND USES THEREOF POLM, HNRNPM, POLRMT ALDH1A1 2068/4885SMN1; SMN2 693/4885TOP1 419/4885
US-20220064710-A1 NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF POLRMT, NSUN2, ADAR ALDH1A1 2687/4885SMN1; SMN2 1132/4885TOP1 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.